Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Dillione Janet	2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O CORMEDIX INC., 400 CONNELL DRIVE, SUITE 5000	3. Date of Earliest Transaction (MM/DD/YYYY) 3/18/2019
(Street) BERKELEY HEIGHTS, NJ 07922 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	3/18/2019		P		42000	A	$1.666 ⁽¹⁾	180909	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	4213		4213	D
Stock Option (Right to Buy Common Stock)	$1.66							⁽³⁾	1/10/2029	Common Stock	75000		75000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	6637		6637	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	13636		13636	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	37500		37500	D
Stock Option (Right to Buy Common Stock)	$0.57							⁽⁴⁾	2/16/2028	Common Stock	40000		40000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	13392		13392	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	15625		15625	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	20833		20833	D
Stock Option (Right to Buy Common Stock)	$2.24							⁽⁵⁾	2/21/2027	Common Stock	40000		40000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	3472		3472	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	4143		4143	D
Stock Option (Right to Buy Common Stock)	$3.03							⁽⁶⁾	8/11/2025	Common Stock	50000		50000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	1415		1415	D
Stock Option (Right to Buy Common Stock)	$3.03							⁽⁷⁾	2/21/2026	Common Stock	95000		95000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	3831		3831	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	2767		2767	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	4335		4335	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	15306		15306	D

Explanation of Responses:
(1)	Represents the weighted average purchase price of the shares purchased from a low of $1.655 to a high of $1.670 per share.
(2)	Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director.
(3)	These options were granted on 01/10/2019. The options vest monthly with 100% vesting on the one year anniversary of the date of grant, subject to continued service on the board.
(4)	These Restricted Stock Units were granted on 2/16/2018. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest in full on the first anniversary of the date of grant, subject to continued service on the board.
(5)	These options were granted on 2/21/2017. The options vest in full on the first anniversary of the date of grant, subject to continued service on the board.
(6)	These options were granted on 8/12/2015. The options vest as follows: 1/3 on 8/12/2015, 1/3 on 8/12/2016, and 1/3 on 8/12/2017.
(7)	These options were granted on 2/21/2016. These options vest in full on the first anniversary of the date of grant, subject to continued service on the board.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Dillione Janet C/O CORMEDIX INC. 400 CONNELL DRIVE, SUITE 5000 BERKELEY HEIGHTS, NJ 07922	X

Signatures
/s/ Alexander M. Donaldson, by Power of Attorney		3/20/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.